Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs SEP 4199 (Primary)
- Indications Bipolar I disorders; Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 01 Jan 2022 Results published in the Journal of Affective Disorders
- 06 Jul 2020 According to a Sunovion Pharmaceuticals media release, it will present the full study data and discussing them with the scientific community at future medical meetings.
- 06 Jul 2020 Topline Results(n=337) published in Sunovion Pharmaceuticals Media Release.